Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.31 |
| ▸ | GLB1 | P16278 | 1/20 | 0.31 |
| ▸ | PPM1B | O75688 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1253774 | 0.73 | HPGD (0.36) | KMT2AMEN1LMNACYP3A4FUCA1 | |
| SCHEMBL17145154 | 0.73 | LMNA (0.37) | KMT2AMEN1LMNACYP3A4ALDH1A1 | |
| SCHEMBL13944890 | 0.72 | FUCA1 (0.32) | KMT2AMEN1LMNACYP3A4FUCA1 | |
| SCHEMBL28354991 | 0.71 | MAPT (0.35) | KMT2ALMNAFUCA1 | |
| SCHEMBL30468187 | 0.68 | TSHR (0.38) | KMT2AMEN1LMNACYP3A4FUCA1 | |
| SCHEMBL3675243 | 0.68 | TSHR (0.38) | KMT2AMEN1LMNACYP3A4FUCA1 | |
| SCHEMBL15144345 | 0.68 | TSHR (0.38) | KMT2AMEN1LMNACYP3A4FUCA1 | |
| SCHEMBL13984986 | 0.68 | TSHR (0.38) | KMT2AMEN1LMNACYP3A4FUCA1 | |
| SCHEMBL3650538 | 0.68 | TSHR (0.38) | KMT2AMEN1LMNACYP3A4FUCA1 | |
| SCHEMBL30468216 | 0.68 | TSHR (0.35) | KMT2AMEN1LMNACYP3A4FUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2178819-A2 | EPOXIDE INTERMEDIATE IN THE TAMIFLU SYNTHESIS | F.HOFFMANN-LA ROCHE AG (CH) | 2010-04-28 | — | — | EP | disclosed |
| US-7473798-B2 | Derivatives of unsaturated, cyclic organic acids | ROCHE PALO ALTO LLC (US) | 2009-01-06 | — | — | US | disclosed |
| US-20070197807-A1 | Derivatives of unsaturated, cyclic organic acids | GABEL RICHARD A | 2007-08-23 | — | — | US | disclosed |
| WO-2007074091-A2 | EPOXIDE INTERMEDIATE IN THE TAMIFLU SYNTHESIS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197807-A1 | Derivatives of unsaturated, cyclic organic acids | ALOX5, VKORC1, ELOVL5 | KMT2A 2221/4885MEN1 4812/4885LMNA 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.